SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies - - SGT-501 has received Orphan Drug Designation and Rare Pediatric Disease Design ...

Background Stereotactic arrhythmia radioablation (STAR) is a novel, non-invasive treatment for therapy-refractory ventricular ... died during follow-up (table 2). Heart failure was the most frequently ...

Atrial fibrillation (Afib) is one of the most common heart rhythm disorders, affecting millions worldwide. It occurs when the ...

Colombo celebrates Indonesia The Indonesian Embassy in Colombo hosted the Indonesian Bazaar and Cultural Show at their ...

When it comes to dream destination, you don’t have to look beyond Colombo’s skyscape. Blending colonial elegance seaside ...

Atrial fibrillation (AF) is the commonest atrial arrhythmia and represents a large burden on modern health services. Large multicentre randomised trials have demonstrated that a rhythm control ...

Varosy PD, Chen LY, Miller AL, et al. Pacing as a treatment for reflex-mediated (vasovagal, situational, or carotid sinus hypersensitivity) syncope: a systematic review for the 2017 ACC/AHA/HRS ...

Just a dozen patients have undergone the new treatment that uses electrical pulses to target problem areas inside the heart.

New findings suggest serious data issues behind a major heart drug’s approval, reigniting concern over its decade-long use. Credit: Stock An investigation has uncovered evidence of significant ...

Five patients here have undergone the new treatment since February 2025. Read more at straitstimes.com. Read more at straitstimes.com.

Globally, about 3 percent of people over the age of 70 suffer from moderate to severe leaky heart valve, with the prevalence of the condition increasing with age.

This pioneering heart rhythm management was applied to a 33-year-old male patient, Ravi (name changed), a car driver by profession from Tripura, Agartala.